The incidence of melanoma in Australia and New Zealand is amongst the highest world-wide. When diagnosed early, melanoma has an overall survival (OS) rate of 100%. However, stage 4 melanoma has an OS of 26% and is amongst the lowest survival rates for stage 4 metastatic cancers. Current frontline therapeutics used in the clinic are successful in preventing progression of disease for a short period of time; however, patients typically relapse within ~ 9 months. In addition, the use of immunotherapy in the clinic has a dismal 30% response rate and patients will typically relapse with the disease. The expression of de novo fatty acid synthesis (DNFA) proteins is increased in metastatic cancers in comparison to healthy tissue. Rapidly dividing cells require de novo fatty acid synthesis to accommodate the increase in demand for lipids to synthesise membrane lipids, produce lipids for protein post-translational modifications and for fatty acid oxidation. The need for new targeted therapeutics in melanoma is essential, we propose to address this need by developing peptide inhibitors to target de novo fatty acid synthesis. We propose using peptide scaffolds cyclic Gomesin and cyclic Tachyplesin, to develop peptide inhibitors that are cell permeable and able to inhibit proteins essential for DNFA.